Sartorius Stedim Biotech S.A.

WBAG:DIM Stock Report

Market Cap: €16.3b

Sartorius Stedim Biotech Valuation

Is DIM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DIM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DIM (€168.45) is trading above our estimate of fair value (€121.07)

Significantly Below Fair Value: DIM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DIM?

Key metric: As DIM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DIM. This is calculated by dividing DIM's market cap by their current earnings.
What is DIM's PE Ratio?
PE Ratio101.4x
Earnings€160.60m
Market Cap€16.28b

Price to Earnings Ratio vs Peers

How does DIM's PE Ratio compare to its peers?

The above table shows the PE ratio for DIM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average87.3x
DIVISLAB Divi's Laboratories
83.4x23.7%₹1.5t
AVTR Avantor
44.4x36.4%US$14.1b
SRT3 Sartorius
187.6x36.4%€13.1b
WAT Waters
33.9x8.6%US$21.3b
DIM Sartorius Stedim Biotech
101.4x31.9%€16.3b

Price-To-Earnings vs Peers: DIM is expensive based on its Price-To-Earnings Ratio (101.4x) compared to the peer average (87.3x).

Price to Earnings Ratio vs Industry

How does DIM's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
DIM 101.4xIndustry Avg. 36.9xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: DIM is expensive based on its Price-To-Earnings Ratio (101.4x) compared to the European Life Sciences industry average (37.1x).

Price to Earnings Ratio vs Fair Ratio

What is DIM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DIM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio101.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate DIM's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DIM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€168.45
€220.67
+31.0%
18.2%€310.00€134.00n/a15
Nov ’25€191.70
€220.67
+15.1%
18.2%€310.00€134.00n/a15
Oct ’25€189.50
€213.93
+12.9%
20.5%€310.00€134.00n/a14
Sep ’25€184.35
€207.31
+12.5%
20.8%€310.00€134.00n/a13
Aug ’25€186.25
€207.31
+11.3%
20.8%€310.00€134.00n/a13
Jul ’25€155.50
€247.17
+58.9%
17.8%€360.00€180.00n/a12
Jun ’25€182.80
€248.83
+36.1%
16.8%€360.00€200.00n/a12
May ’25€209.10
€251.33
+20.2%
16.9%€360.00€200.00n/a12
Apr ’25€271.30
€261.23
-3.7%
15.8%€360.00€205.00n/a12
Mar ’25€256.10
€254.69
-0.5%
17.1%€360.00€190.00n/a14
Feb ’25€225.90
€253.12
+12.1%
18.3%€360.00€190.00n/a14
Jan ’25€238.60
€230.56
-3.4%
14.8%€310.00€175.00n/a12
Dec ’24€206.00
€224.31
+8.9%
14.5%€310.00€175.00n/a12
Nov ’24€176.20
€252.42
+43.3%
22.5%€390.00€175.00€191.7012
Oct ’24€221.90
€308.73
+39.1%
12.3%€390.00€265.00€189.5011
Sep ’24€259.70
€306.45
+18.0%
12.5%€390.00€270.00€184.3511
Aug ’24€282.10
€303.73
+7.7%
13.5%€390.00€250.00€186.2511
Jul ’24€213.90
€334.18
+56.2%
22.7%€530.00€250.00€155.5011
Jun ’24€245.50
€363.82
+48.2%
18.5%€530.00€285.00€182.8011
May ’24€257.60
€376.70
+46.2%
17.6%€530.00€300.00€209.1010
Apr ’24n/a
€395.27
0%
10.5%€455.00€306.00€271.3011
Mar ’24n/a
€395.91
0%
10.7%€455.00€306.00€256.1011
Feb ’24€320.10
€394.73
+23.3%
10.3%€455.00€306.00€225.9011
Jan ’24€310.30
€411.20
+32.5%
12.3%€470.00€290.00€238.6010
Dec ’23€323.70
€411.20
+27.0%
12.3%€470.00€290.00€206.0010
Nov ’23€314.60
€418.45
+33.0%
13.0%€497.00€290.00€176.2011

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

ALM

€8.41

7D

1.3%

1Y

-2.8%

Teva Pharmaceutical Industries

US$18.6b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$15.45

7D

-5.2%

1Y

84.8%

Bayer

€19.9b

Together its subsidiaries, operates as a life science company worldwide.

BAYN

€20.20

7D

-17.4%

1Y

-40.3%